Close

VIDA Diagnostics and Olympus Respiratory America collaborates for Delivery of Quantitative Lung Imag

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

VIDA Diagnostics, Inc., the pioneer in quantitative lung analysis software and services, today announced a collaboration with Olympus Respiratory America, a leading provider of therapeutic pulmonary devices. Under the agreement, Olympus will distribute VIDA's lung analysis services with its Spiration® IBV Valve System in Europe and Australia to aid physicians in patient selection.
"Our partnership with Olympus Respiratory America is an exciting breakthrough. It is an opportunity for pulmonary physicians to use imaging biomarkers to select patients more likely to respond to novel pulmonary therapies and positively impact the lives of severe emphysema patients," said Susan A. Wood, Ph.D, President and CEO of VIDA.
Successful treatment for patients with severe emphysema is impacted by the quality and accuracy of information provided to the care team. It is important to properly characterize, locate and quantify disease well beyond the capabilities of a basic pulmonary function test to select suitable patients for the Spiration IBV Valve therapy. Criteria for patient selection include emphysema severity, fissure integrity scoring, and perfusion. With the partnership between VIDA and Olympus Respiratory America, Spiration IBV Valve customers and their patients will benefit from increased information available with precise imaging analytics.
"The interventional pulmonary field is advancing with the emergence of both novel therapies for patients with emphysema, and the essential analytics to accurately match the patient to the therapy for greater response," said Felix Herth, MD, Ph.D, Chairman, Department of Pneumology and Critical Care Medicine at ThoraxKlinik, University of Heidelberg. "It is essential that, as pulmonary clinicians, we treat the patient safely, effectively and cost efficiently. VIDA's solution increases our ability to match the right treatment to the right patient at the right time."

Latest stories

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back